secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0000805928-22-000054
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q1 rev flat at $31M, net loss widens to $0.20/sh; Avance Phase 3 hits endpoint
--------------------------------------------------------------------------------

- Net revenue $31.0M flat YoY; adjusted net loss $8.5M ($0.20/sh) vs $3.1M ($0.08) prior year.
- Cash and investments $73.7M at Mar 31, down from $90.3M at Dec 31, 2021.
- Phase 3 RECON study of Avance Nerve Graft met primary endpoint for sensory function; BLA submission planned H2 2023.
- Avance showed statistical superiority over conduits for gaps >12mm (p=0.021) and faster recovery (p=0.037).
- 2022 revenue guidance reaffirmed $135-142M; gross margin above 80%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592822000054/0000805928-22-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592822000054/axgn-20220504.htm
  HTML page:      https://secwatch.observer/filing/0000805928-22-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer